SCHEMBL7141855

SCHEMBL7141855

Fc1ccc(-c2c[nH]c(-c3ccccc3)n2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
MAPK13 O15264 2/20 0.44
GCGR P47871 2/20 0.44
MAPK12 P53778 2/20 0.44
MAPK11 Q15759 2/20 0.44
MAPK14 Q16539 2/20 0.44
ALOX5 P09917 1/20 0.44
ALDH1A3 P47895 2/20 0.44
TNKS O95271 1/20 0.44
TNKS2 Q9H2K2 1/20 0.44
PARP2 Q9UGN5 1/20 0.44
MAPT P10636 3/20 0.43
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26110507 1.00 KDM4E (0.45) KDM4ENPC1RAB9ASMN1; SMN2MAPK13
SCHEMBL15029205 0.93 MAPK1 (0.42) KDM4ENPC1RAB9ASMN1; SMN2MAPK13
SCHEMBL2838619 0.91 HPGDS (0.50) KDM4ENPC1RAB9ASMN1; SMN2MAPK13
SCHEMBL4847155 0.89 HPGDS (0.43) KDM4ENPC1RAB9ASMN1; SMN2MAPK13
SCHEMBL7139559 0.89 HPGDS (0.43) KDM4ENPC1RAB9ASMN1; SMN2MAPK13
SCHEMBL528246 0.89 MEN1 (0.46) KDM4ENPC1RAB9ASMN1; SMN2MAPT
SCHEMBL2843337 0.88 HPGDS (0.48) KDM4ENPC1RAB9ASMN1; SMN2MAPK13
SCHEMBL27762157 0.86 MAPK13 (0.49) KDM4ESMN1; SMN2MAPK13MAPK12MAPK11
SCHEMBL4960670 0.84 ALDH1A3 (0.42) KDM4ENPC1RAB9ASMN1; SMN2MAPK13
SCHEMBL8110936 0.84 IDO1 (0.47) KDM4ESMN1; SMN2MAPK13MAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6515133-B1 Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. NEUROGEN CORPORATION 2003-02-04 US claimed
US-6121260-A Method of treating conditions susceptible to modulation of NPY receptors with diarylimidazole derivatives NEUROGEN CORPORATION (US) 2000-09-19 US claimed
CN-1265033-A Certain diarylimidaozle derivatives, new class of NPY speific ligands NEUROGEN CORP (US) 2000-08-30 CN claimed
EP-0996443-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 2000-05-03 EP claimed
WO-1999001128-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 1999-01-14 WO claimed
US-20250215572-A1 SURFACE TREATMENT AGENT FOR COPPER OR COPPER ALLOY SHIKOKU CHEMICALS CORPORATION (JP) 2025-07-03 US disclosed
EP-4506488-A1 SURFACE TREATMENT AGENT FOR COPPER OR COPPER ALLOY Shikoku Chemicals Corporation (JP) 2025-02-12 EP disclosed
CN-118922584-A Surface treating agent for copper or copper alloy 四国化成工业株式会社 2024-11-08 CN disclosed
WO-2023190263-A1 SURFACE TREATMENT AGENT FOR COPPER OR COPPER ALLOY 四国化成工業株式会社 2023-10-05 WO disclosed
EP-3102207-B1 2,4,5-TRI-SUBSTITUTED AZOLE-BASED CASEIN KINASE 1 INHIBITORS AS INDUCERS FOR CARDIOMYOGENESIS AGENCY SCIENCE TECH & RES (SG) 2022-05-11 EP disclosed
US-8846948-B2 Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-09-30 US disclosed
US-8796467-B2 Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-08-05 US disclosed
CN-101448978-B Surface treating agent for metal and use thereof SHIKOKU CHEM 2012-06-13 CN disclosed
CN-102121108-A Compound OSP treating agent for lead-free printed circuit board GUANGDONG TONESET SCIENCE & TECHNOLOGY CO LTD 2011-07-13 CN disclosed
CN-101448978-A Surface treating agent for metal and use thereof SHIKOKU CHEM (JP) 2009-06-03 CN disclosed
US-6515133-B1 Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. NEUROGEN CORPORATION 2003-02-04 US disclosed
US-6121260-A Method of treating conditions susceptible to modulation of NPY receptors with diarylimidazole derivatives NEUROGEN CORPORATION (US) 2000-09-19 US disclosed
CN-1265033-A Certain diarylimidaozle derivatives, new class of NPY speific ligands NEUROGEN CORP (US) 2000-08-30 CN disclosed
EP-0996443-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 2000-05-03 EP disclosed
WO-1999001128-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 1999-01-14 WO disclosed